Search clinical trials for: AZD9742

Total 55 results

AstraZeneca
Quintiles, Inc.

Completed

This is a Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of AZD9742 After Single IV Doses in Healthy Subjects

Healthy

United States
AstraZeneca

Withdrawn

Study in Healthy Males to Assess Distribution, Metabolism, and Excretion of Radio-labelled AZD9742 Administered as a 2-hour Infusion

Healthy

United States
AstraZeneca

Completed

AZD9742 Single and Multiple Ascending Dose Study in Healthy Male and Female Japanese Subjects

Healthy

United States
AstraZeneca

Completed

A Study in Healthy Volunteers to Assess Safety and Blood Levels of AZD9742 After Multiple Doses Over 14 Days

Healthy

United States
AstraZeneca

Completed

Assessing the Safety and Tolerability of a Single IV Dose of AZD9742 in Healthy Elderly Male and Female Subjects

Healthy | Elderly | Tolerability

United States
AstraZeneca

Completed

Phase I Double-blind, Placebo-controlled Study of AZD7442

COVID-19

Japan
AstraZeneca

Completed

A Study to Evaluate the Safety and Tolerability of AZD7442 in Healthy Chinese Adults

Healthy Volunteer | Coronavirus Disease 2019 (COVID-19)

China
Ardelyx

Completed

AZD1722 Open Label, Absorption Distribution Metabolism and Excretion Study

Healthy Volunteers

United Kingdom
Ardelyx
AstraZeneca

Completed

Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis

End Stage Renal Disease | ESRD | Chronic Kidney Disease Stage 5

United States
AstraZeneca

Completed

A Study to Evaluate the Safety and Tolerability of AZD7442 in Chinese Adults

Coronavirus Disease 2019 (COVID-19)

China
Ardelyx

Completed

A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C (T3MPO-3)

Constipation Predominant Irritable Bowel Syndrome

United States
Ardelyx
AstraZeneca

Completed

A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria

Type 2 Diabetes Mellitus | Chronic Kidney Disease

United States
Ardelyx

Completed

Dose Finding Study to Treat High Phosphate Levels in the Blood.

Hyperphosphatemia

United States, Poland, United Kingdom, Slovakia
Ardelyx

Completed

An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)

Hyperphosphatemia

United States
Ardelyx

Completed

The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)

Constipation Predominant Irritable Bowel Syndrome

United States
AstraZeneca

Completed

A Study to Compare the Efficacy and Safety of 2 Dosing Regimens of IV Infusions of AZD9773 (CytoFab™) With Placebo in Adult Patients With Severe Sepsis and/or Septic Shock

Septic Shock | Severe Sepsis

Czech Republic, France, Spain, Finland, Canada, Australia, Belgium
AstraZeneca

Completed

AZD9773 Dose Escalation Study

Severe Sepsis

United States
Ardelyx

Completed

A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C (T3MPO-1)

Constipation Predominant Irritable Bowel Syndrome

United States
Ardelyx

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RDX5791 in Healthy Volunteers

Healthy
Ardelyx

Completed

A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C (T3MPO-2)

Constipation Predominant Irritable Bowel Syndrome

United States
Ardelyx
AstraZeneca

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of AZD1722 in Healthy Male and Female Japanese Subjects

Healthy Volunteer

United States
AstraZeneca
Parexel

Completed

AZD7442 - a Potential Combination Therapy for the Prevention and Treatment of COVID-19

COVID-19

United Kingdom
Ardelyx

Completed

D5611C00003 - Food Interaction Study With AZD1722 Tablet in Healthy Subjects

Healthy Volunteers Food Interaction Study

United States
AstraZeneca

Completed

A Study to Assess Safety,and Tolerability of 2 Doses of AZD9773 (CytoFab™) in Japanese With Severe Sepsis/Septic Shock

Septic Shock | Severe Sepsis

Japan
University of Rome Tor Vergata

Completed

EVALUATION OF DIFFERENT PROPHYLACTIC INTERVENTIONS TOWARD COVID-19 IN SOLID ORGAN TRANSPLANT PATIENTS

COVID-19 Pandemic | Transplant-Related Disorder

Italy
AstraZeneca
Iqvia Pty Ltd

Active, not recruiting

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult. (PROVENT)

COVID-19

United States, Belgium, France, Spain, United Kingdom
Ardelyx

Completed

Safety, Tolerability, and Pharmacodynamics of RDX5791 in Healthy Volunteers

Healthy
FibroGen
AstraZeneca

Completed

Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS)

Anemia | Myelodysplastic Syndrome

China
AstraZeneca

Active, not recruiting

AZD7442 Pharmacokinetics, Pharmacodynamics, and Safety Evaluation in Pediatrics (TRUST)

SARS-CoV-2

United States, Belgium, United Kingdom, Brazil, Germany
FibroGen
AstraZeneca; Astellas Pharma Inc

Terminated

Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden

Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)

United States, Australia, Belgium, Germany, Israel, Italy, Korea, Republic of, Russian Federation, Spain, United Kingdom, France, Turkey, Canada, Denmark, India, Poland
AstraZeneca

Not yet recruiting

eVusheld Assessment reaL wORld Effectiveness in DoD Health System (VALOR DoD)

COVID-19; SARS-CoV-2; 2019 Novel Coronavirus Disease
Ardelyx

Completed

A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis

Hyperphosphatemia

United States
Ardelyx

Completed

To Evaluate the Effect of AZD1722 on the Pharmacokinetics of Oral Midazolam in Healthy Volunteers

Healthy Volunteers

United States
AstraZeneca

Terminated

A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19 (ENDURE)

Coronavirus Disease 2019 (COVID-19)

United States
FibroGen
AstraZeneca; Astellas Pharma Europe B.V.

Completed

Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants (Himalayas)

Anemia in Incident Dialysis Patients

Russian Federation, Bulgaria, Thailand, United States, Argentina, Chile, Colombia, Korea, Republic of, Latvia, Malaysia, Mexico, Poland, Romania, Taiwan, Ukraine
Ardelyx

Completed

To Assess the Effect of AZD1722 on the Pharmacokinetics of Cefadroxil in Healthy Volunteers

Healthy Volunteers

United States
MediMergent, LLC

Terminated

Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2

SARS-CoV-2 Infection

United States
FibroGen
AstraZeneca; Astellas Pharma Europe B.V.

Completed

A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis

CKD Anemia

United States, Australia, Thailand, Korea, Republic of, Malaysia, Mexico, Taiwan, New Zealand, Argentina, Chile, Colombia, Hong Kong, Peru, Philippines, Puerto Rico, Singapore
Ardelyx
AstraZeneca

Completed

A Phase 1 Study to Examine the Effect of Renvela on the Pharmacodynamics of AZD1722

Healthy

United States
AstraZeneca
Iqvia Pty Ltd

Completed

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults (STORM CHASER)

COVID-19

United States, United Kingdom
AstraZeneca

Completed

Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults (TACKLE)

COVID-19

United States, Spain, United Kingdom, Brazil, Germany, Ukraine, Japan, Italy, Poland, Russian Federation, Mexico, Czechia, Argentina, Hungary, Peru
AstraZeneca

Terminated

Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan

Cancer | Advanced Solid Tumors | Advanced Solid Malignancies

United States
Ardelyx
AstraZeneca

Completed

A Phase 1 Study to Examine the Pharmacodynamics of Different AZD1722 Formulations

Healthy

United States
National Institute of Allergy and Infectious Diseases...
National Heart, Lung, and Blood Institute (NHLBI); AstraZeneca; University of... and other collaborators

Active, not recruiting

AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

COVID-19

United States, Denmark, Greece, Poland, Singapore, Spain, Switzerland, Uganda, United Kingdom
AstraZeneca

Active, not recruiting

Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study (SUPERNOVA)

COVID-19, SARS-CoV-2

United States, Belgium, Canada, France, Spain, Denmark, Thailand, Vietnam, Korea, Republic of, United Kingdom, Malaysia, Israel, Taiwan, Australia, Germany, Poland, Singapore, United Arab Emirates
National Institute of Allergy and Infectious Diseases...
Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; AIDS Clinical Trials... and other collaborators

Completed

ACTIV-2: A Study for Outpatients With COVID-19

Covid19 | Coronavirus

United States, Argentina, Brazil, Guatemala, Mexico, Philippines, Puerto Rico, South Africa, Canada
AstraZeneca

Completed

Study to Assess Safety of AZD7762 Administered Alone and in Combination With Gemcitabine in Patients With Advanced Solid Malignancies

Solid Tumors

United States
AstraZeneca

Completed

Study to Evaluate Pharmacokinetic Comparability Between AZD7442 Co-formulation (AZD8895 + AZD1061) vs AZD8895 and AZD1061 Individually in Adult Healthy Participants

Corona Virus Disease

United States
AstraZeneca

Terminated

Safety and Tolerability Study of AZD7762 in Combination With Gemcitabine

Cancer | Solid Tumors | Advanced Solid Malignancies

Japan
AstraZeneca

Completed

Open Label Study, Assessing the Effect of Diltiazem or Ketoconazole on the Pharmacokinetics of AZD9742 in Healthy Volunteers

Pharmacokinetics

United States

3

Subscribe